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Value of the data {#sec0001a}
=================

•The data contains the general synthetic procedure for bromination of the methyl groups of 3,5-bis(alkoxycarbonyl)−2,6-dimethyl-4-aryl-1,4-dihydropyridine which may serve as valuable guidance for organic chemists.•The obtained 2,6-di(bromomethyl)−1,4-dihydropyridines can be used as intermediates for synthesis of various lipid-like compounds based on 1,4-dihydropyridine cycle.•The data provides characterisation of original compounds - 2,6-di(bromomethyl)−3,5-bis(alkoxycarbonyl)−4-aryl-1,4-dihydropyridines which have not been reported before.•Additionally, described synthetic procedure and obtained spectral data will be useful for preparation and structure elucidation of brominated derivatives in related heterocyclic systems.•Besides the use of 2,6-di(bromomethyl) derivatives in synthesis of cationic 1,4-dihydropyridines their applications may be extended to other reactions of bromomethyl groups.

1. Data description {#sec0001}
===================

Bromination of the methyl groups of 2,6-dimethyl-1,4-dihydropyridines is a key step in procedure of synthesis of 1,4-dihydropyridines with cationic moieties for further biological studies \[[@bib0001],[@bib0002]\]. The dataset presents the synthesis and physicochemical characterisation of 2,6-di(bromomethyl)−3,5-bis(alkoxycarbonyl)−4-aryl-1,4-dihydropyridines **2** which data have not been described before. Previously 2,6-di(bromomethyl)−3,5-bis(alkoxycarbonyl)−4-phenyl-1,4-dihydropyridines **2a-c** were applied for synthesis of amphiphilic 1,4-dihydropyridines (1,4-DHP) without any purification and identification [@bib0001]. Synthesis of other 2,6-di(bromomethyl)−3,5-bis(alkoxycarbonyl)−4-aryl-1,4-dihydropyridines **2d-f** is reported herein. These compounds **2a-f** are prepared for further use in synthesis of cationic 1,4-DHPs and other modifications giving new sources of biologically active compounds. Parent 2,6-dimethyl-1,4-DHPs **1a-c** [@bib0001] and **1d-f** [@bib0003] were synthesised by the previously described procedures. The synthetic scheme and also the structures of all 2,6-di(bromomethyl)−1,4-dihydropyridines are depicted in [Fig. 1](#fig0001){ref-type="fig"}. Structures of new 2,6-di(bromomethyl)−1,4-dihydropyridines **2** ([Table 1](#tbl0001){ref-type="table"}) were confirmed by ^1^H and ^13^C NMR spectra.Fig. 1Scheme of the synthesis of 2,6-di(bromomethyl)−1,4-dihydropyridines **2** from the corresponding 3,5-bis(alkoxycarbonyl)−2,6-dimethyl-4-phenyl-1,4-dihydropyridines **1** in the reaction with N-bromosuccinimide (NBS). Structures of new 2,6-di(bromomethyl)−1,4-dihydropyridines **2a-f** ([Table 1](#tbl0001){ref-type="table"}).Fig. 1Table 1Structures of compounds.Table 1NrRR'R"**a**C~14~H~29~-nHH**b**C~16~H~33~-nHH**c**C~12~H~25~-nHCH~3~**d**C~14~H~29~-nOHH**e**C~10~H~24~-nOCH~3~H**f**C~10~H~24~-nOC~7~H~15~-nH

2. Experimental design, materials and methods {#sec0002}
=============================================

2.1. General information {#sec0003}
------------------------

All reagents and solvents were purchased from commercial suppliers (ACROS, Sigma-Aldrich) and used without further purification. Organic solutions were concentrated under reduced pressure on a rotary evaporator (Buchi). Reactions were monitored with thin-layer chromatography (TLC) on Silica gel 60 F254 aluminium sheets 20 × 20 cm; eluent: EtOAc:hexane=1:5. Flash column chromatography was accomplished using flow chromatography (Armen Instrument). Silica gel (Merck, Silica gel 60, 35--70 µm) was used for column chromatography with gradient elution: EtOAc:hexane 0:100 to 15:85%. Elemental analyses were determined on an Elemental Combustion System ECS 4010 (Costech Instruments). Melting points were determined on an OptiMelt (SRS Stanford Research Systems).

2.2. General procedure for synthesis of 2,6-di(bromomethyl)−1,4-dihydropyridines 2 {#sec0004}
----------------------------------------------------------------------------------

To a solution of 2,6-dimethyl-1,4-DHP **1a-f** (5.00 mmol) in methanol (100 mL) a solution of NBS (10.40 mmol) in methanol (50 mL) was added dropwise. The reaction mixture was stirred at rt for 2 h, completion of the reaction was monitored by TLC.

In the case of comp. **2a,b** the yellow precipitate was filtered off and washed with water; for the comp. **2c-f** the solvent was evaporated and the residue was purified by flash-chromatography. The compounds **2d-f** compounds were found to be unstable during the storage due to lactonisation into 8-aryl-5,8-dihydro-1*H*,3*H*-difuro\[3,4-*b*:3′,4′-*e*\]pyridine-1,7(4*H*)‑dione derivatives [@bib0004]. Satisfactory NMR data were obtained after two purifications by chromatography.

*Ditetradecyl 2,6-bis(bromomethyl)−4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate* (**2a**)

![](fx1.gif)

Yield: 73%. Yellow powder; m.p. 84--86 °C; ^1^H NMR (300 MHz, CDCl~3~) δ: 7.28 -- 7.14 (m, 5H) overlap with CHCl~3~, 6.45 (s, 1H), 5.02 (s, 1H), 4.93 and 4.63 (AB-system, *J* = 11.6 Hz, 4H), 4.12 (td, *J* = 6.6, 2.7 Hz, 4H), 1.66 -- 1.56 (m, 4H), 1.26 (s, 44H), 0.92 -- 0.85 (m, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~) δ: 166.40, 145.78, 141.78, 128.40, 128.10, 127.03, 106.25, 64.95, 40.26, 32.08, 29.87, 29.85, 29.83, 29.79, 29.72, 29.53, 29.44, 28.73, 27.52, 26.21, 22.85, 14.28 ppm. Anal. Calcd. for C~43~H~69~Br~2~NO~4~: C%, 62.69; H%, 8.44; N%, 1.70. Found: C%, 62.67; H% 8.45; N% 1.67.

*Dihexadecyl 2,6-bis(bromomethyl)−4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate* (**2b**)

![](fx2.gif)

Yield: 53%. Yellow powder; m.p. 86--88 °C; ^1^H NMR (300 MHz, CDCl~3~) δ: 7.28 -- 7.15 (m, 5H) overlap with CHCl~3~, 6.44 (s, 1H), 5.02 (s, 1H), 4.93 and 4.63 (AB-system, *J* = 11.6 Hz, 4H), 4.07 (td, *J* = 6.6, 2.7 Hz, 4H), 1.66 -- 1.56 (m, 4H), 1.34 -- 1.19 (m, 52H), 0.92 -- 0.84 (m, 6H) pmm. ^13^C NMR (100 MHz, CDCl~3~) δ: 166.40, 145.78, 141.76, 128.40, 128.10, 127.03, 106.26, 64.95, 40.26, 32.09, 29.88, 29.83, 29.79, 29.73, 29.53, 29.45, 28.73, 27.52, 26.21, 22.85, 14.28 ppm. Anal. Calcd. for C~47~H~77~Br~2~NO~4~: C%, 64.15; H%, 8.82; N%, 1.59. Found: C%, 64.40; H% 8.86; N% 1.57.

*Didodecyl 2,6-bis(bromomethyl)−1-methyl-4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate* (**2c**)

![](fx3.gif)

Yield: 48%. Yellow oil; ^1^H NMR (300 MHz, CDCl~3~) δ: 7.23 -- 7.13 (m, 5H), 5.24 (s, 1H), 5.03 -- 4.92 (m, 2H), 4.88 -- 4.77 (m, 2H), 4.16 (t, *J* = 6.6 Hz, 4H), 3.47 (s, 3H), 1.72 -- 1.61 (m, 4H), 1.39 -- 1.20 (m, 36H), 0.92 -- 0.85 (m, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~) δ: 166.41, 147.39, 144.01, 128.49, 127.00, 126.84, 108.91, 65.16, 37.98, 32.10, 32.07, 29.83, 29.79, 29.76, 29.72, 29.51, 29.43, 28.75, 26.22, 24.95, 22.84, 14.27 ppm.

*Ditetradecyl 2,6-bis(bromomethyl)−4-(4-hydroxyphenyl)−1,4-dihydropyridine-3,5-dicarboxylate* (**2d**)

![](fx4.gif)

Yield: 17%. Yellow oil; ^1^H NMR (300 MHz, CDCl~3~) δ: 7.14 -- 7.09 (m, 2H), 6.70 -- 6.65 (m, 2H), 6.42 (br.s, 1H), 4.95 (s, 1H), 4.89 and 4.63 (AB-system, *J* = 11.6 Hz, 4H), 4.58 (br.s, 1H), 4.11 -- 4.04 (m, 4H), 1.66 -- 1.56 (m, 4H), 1.34 -- 1.20 (m, 44H), 0.91 -- 0.85 (m, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~) δ: 166.73, 154.82, 141.73, 138.14, 129.27, 115.26, 106.30, 65.05, 39.35, 32.05, 29.84, 29.82, 29.80, 29.78, 29.71, 29.50, 29.43, 28.69, 27.39, 26.20, 22.82, 14.25 ppm.

*Didecyl 2,6-bis(bromomethyl)−4-(4-methoxyphenyl)−1,4-dihydropyridine-3,5-dicarboxylate* (**2e**)

![](fx5.gif)

Yield: 52%. Yellow oil; ^1^H NMR (300 MHz, CDCl~3~) δ: 7.20 -- 7.14 (m, 2H), 6.78 -- 6.73 (m, 2H), 6.43 (br.s, 1H), 4.96 (s, 1H), 4.90 and 4.64 (AB-system, *J* = 11.5 Hz, 4H), 4.12 -- 4.03 (m, 4H), 3.75 (s, 3H), 1.67 -- 1.56 (m, 4H), 1.34 -- 1.22 (m, 28H), 0.91 -- 0.85 (m, 6H) ppm. ^13^C NMR (100 MHz, CDCl~3~) δ: 166.49, 158.61, 141.59, 138.30, 129.13, 113.71, 106.36, 64.91, 55.27, 39.34, 32.98, 32.04, 29.72, 29.47, 29.44, 28.73, 27.50, 26.21, 22.83, 14.25 ppm.

*Didecyl 2,6-bis(bromomethyl)−4-(4-(heptyloxy)phenyl)−1,4-dihydropyridine-3,5-dicarboxylate* (**2f**)

![](fx6.gif)

Yield: 15%. Yellow oil; ^1^H NMR (300 MHz, CDCl~3~) δ: 7.17 -- 7.12 (m, 2H), 6.77 -- 6.72 (m, 2H), 6.41 (br.s, 1H), 4.95 (s, 1H), 4.91 and 4.63 (AB-system, *J* = 11.5 Hz, 4H), 4.12 -- 4.02 (m, 4H), 3.88 (t, *J* = 6.6 Hz, 2H), 1.80 -- 1.68 (m, 2H), 1.67 -- 1.56 (m, 4H), 1.46 -- 1.18 (m, 36H), 0.91 -- 0.85 (m, 9H) ppm. ^13^C NMR (100 MHz, CDCl~3~) δ: 166.49, 158.25, 141.41, 138.03, 129.11, 114.27, 106.50, 68.02, 64.90, 39.39, 32.07, 31.94, 29.75, 29.74, 29.50, 29.48, 29.45, 29.23, 28.75, 27.61, 26.23, 26.19, 22.85, 14.27 ppm.
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